期刊
BLOOD
卷 136, 期 10, 页码 1161-1168出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020005064
关键词
-
类别
资金
- Danish Cancer Society
- Danish Childhood Cancer Foundation
- Swedish Childhood Cancer Foundation
- Nordic Cancer Union
- Otto Christensen Foundation
- University Hospital Rigshospitalet
- Novo Nordic Foundation
- National Institutes of Health, National Institute of General Medical Sciences [R01GM118578, P50GM115279]
- Alex's Lemonade Stand Foundation
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate genetic factors associated with MTX metabolism, we performed a genome-wide association study in 447 ALL cases from the Nordic Society for Pediatric Haematology and Oncology ALL2008 study, validating results in an independent set of 196 patients. The intergenic single-nucleotide polymorphism rs1382539, located in a regulatory element of DHFR, was associated with increased levels of short-chain MTX polyglutamates (P = 1.1 x 10(-8)) related to suppression of enhancer activity, whereas rs35789560 in FPGS (p.R466C, P = 5.6 x 10(-9)) was associated with decreased levels of long-chain MTX polyglutamates through reduced catalytic activity. Furthermore, the FPGS variant was linked with increased relapse risk (P = .044). These findings show a genetic basis for interpatient variability in MTX response and could be used to improve future dosing algorithms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据